

## Streamlining Medication Use during COVID-19

*This guideline is applicable to all care settings, though all medication changes should be person-centered and based on individualized assessment of clinical circumstances, including therapeutic indication, past medical history, goals of care, and health region or provincial drug formulary.*

### Purpose:

- Consider streamlining medication use in order to reduce repeated contact with care providers, thereby preserving PPE, reducing risk of viral transmission and creating efficiencies in caregiver workload.
- Please consult and collaborate with site or team pharmacists to implement the strategies below.
- If individuals are receiving nutritional supplements with their medications, please adjust this therapy, as appropriate, based on the new medication regimen selected.

### Approach:

- Accurate and timely communication at transitions of care is essential to ensuring patient/client/resident safety. Where applicable, all changes from home medication regimens must be communicated on transfer and discharge medication reconciliation forms/prescriptions. Clearly document care plans for all medication changes that require re-evaluation and/or ongoing monitoring by the next care provider.
- Prioritize medication changes that are:
  - Essential for infection control (especially measures to reduce duration/frequency/risk of medication administration among people with known or suspected COVID-19)
  - Low risk, easy to evaluate, and can be done immediately. Avoid changes that are riskier, time consuming or necessitate increased monitoring.
- Streamline medication use by:

| Strategy  | Description (please see Appendix for specific examples)  |
|---|--|
| <p><b>Deprescribing/ stopping unnecessary medications</b><br/>See <a href="https://deprescribing.org/">https://deprescribing.org/</a> and <a href="https://medstopper.com">https://medstopper.com</a> for specific deprescribing guidelines</p> | <ul style="list-style-type: none"> <li>• Reassess all therapies and discontinue or taper medications no longer needed</li> <li>• Reassess and discontinue medications that provide limited clinical benefit</li> <li>• Discontinue medications no longer aligned with goals of care</li> <li>• Reassess and temporarily discontinue select medications where interruption will not result in a clinically significant impact during the COVID pandemic</li> </ul>                                |
| <p><b>Simplifying medication regimens</b></p>   | <ul style="list-style-type: none"> <li>• Use standard administration times and minimize doses that are not aligned with standard times               <ul style="list-style-type: none"> <li>○ Exceptions: medications that require precise dosing times (antibiotics, chemotherapy, antiparkinsonian medications, medications that must be given with meals e.g. short acting insulin, medications that have significant drug interactions with one another or with food)</li> </ul> </li> </ul> |

|  |   |
|--|---|
|  | <ul style="list-style-type: none"> <li>• Use medications with the lowest frequency of dosing where there are multiple equally effective Formulary medications available</li> <li>• Change from short acting to long acting formulations, as clinically appropriate</li> </ul> |
| <b>Reducing the frequency of medication- associated monitoring</b> | <ul style="list-style-type: none"> <li>• Minimize monitoring in stable patients</li> <li>• For new therapy select medications that minimize monitoring, where possible</li> <li>• Bundle medication monitoring with other labs, when possible</li> </ul>                      |

## Appendix: Specific Examples for Streamlining Medication Use during COVID-19

| Strategy  | Description  | Specific Examples (note: not an extensive list) <sup>1</sup>   |
|---|--|--|
| <b>Deprescribing/ stopping unnecessary medications</b><br><br>See <a href="https://deprescribing.org/">https://deprescribing.org/</a> and <a href="https://medstopper.com">https://medstopper.com</a> for specific deprescribing guidelines | Reassess all therapies and discontinue or taper medications no longer needed                   | <ul style="list-style-type: none"> <li>• proton pump inhibitors (PPIs)</li> <li>• benzodiazepines, antipsychotics</li> <li>• antihyperglycemics in adults greater than 65 years of age with Type 2 diabetes<sup>2</sup></li> <li>• cholinesterase inhibitors</li> <li>• high dose opioids for chronic non-cancer pain<sup>2-3</sup></li> <li>• PRN nasal sprays; lubricating eye drops</li> </ul>                        |
|   | Reassess and discontinue medications that provide limited clinical benefit                     | <ul style="list-style-type: none"> <li>• docusate sodium, docusate calcium<sup>4</sup></li> <li>• multivitamins</li> <li>• herbal products (e.g. glucosamine, cranberry)</li> </ul>  |
|   | Discontinue medications no longer aligned with goals of care                                   | <ul style="list-style-type: none"> <li>• statins in patients with comfort-oriented goals<sup>5-7</sup></li> </ul>  |
|   | Reassess and temporarily discontinue medications during the COVID pandemic                     | <ul style="list-style-type: none"> <li>• calcium, magnesium, vitamin B12, vitamin D (consult a registered dietitian if applicable)</li> <li>• bisphosphonates (alendronate, risedronate)</li> </ul>  |
| <b>Simplifying medication regimens</b>  | Use standard administration times and minimize doses that are not aligned with standard times* | <ul style="list-style-type: none"> <li>• consider changing all dosing to BID instead of q12h (or vice versa)</li> <li>• levothyroxine: give with other medications or with food and adjust dose as required</li> <li>• warfarin: give with either supper, or HS medications</li> <li>• furosemide BID: give once daily (low dose) or give with meals AM and noon or AM and supper (as clinically appropriate)</li> </ul> |

| Strategy                        | Description   | Specific Examples (note: not an extensive list) <sup>1</sup>  |  |
|---------------------------------|---|---|--|
| Simplifying medication regimens |   | <ul style="list-style-type: none"> <li>bisphosphonates: change from daily to once weekly dosing; give weekly on same day for all patients</li> <li>select agents as appropriate that can be bundled with hemodialysis (e.g. cefazolin instead of ceftriaxone for uncomplicated SSTIs)</li> </ul> <p><b>*Exceptions:</b> medications that require precise dosing times (antibiotics, chemotherapy, antiparkinsonian medications, medications that must be given with meals e.g. short acting insulin, medications that have significant drug interactions with one another or with food)</p> |  |
|                                 | Use medications with the lowest frequency of dosing where there are equally effective Formulary medications available | <b>Consider:</b><br>bisoprolol once daily<br>amoxicillin-clavulanate 875/125 mg BID<br>rivaroxaban once daily (new start)<br>azithromycin once daily  | <b>Instead of:</b><br>metoprolol BID<br>amoxicillin-clavulanate 500/125 mg TID<br>apixaban or dabigatran BID |
|                                 |   | ceftriaxone q24h  | clarithromycin BID (except for <i>H pylori</i> )<br>cefazolin q8h (where clinically appropriate)             |
|                                 |   | low molecular weight heparin once daily (e.g. dalteparin) for VTE prophylaxis   | heparin BID  |
|                                 | Other strategies  | <b>Consider:</b><br>combination eye drops (e.g. Cosopt, Combigan)   | <b>Instead of:</b><br>single agent eye drops (where possible)  |
|                                 |   | nitroglycerin patch 12 hrs on/12 hrs off  | isosorbide TID   |
|                                 | Other strategies  | once daily PPI  | ranitidine BID or TID; PPI BID   |
|                                 |   | cetirizine once daily   | diphenhydramine q4-6h  |
|                                 |   | naproxen BID or celecoxib once daily  | ibuprofen TID or QID   |
|                                 |   | vitamin D 10,000 units weekly   | vitamin D 1,000 units daily  |
|                                 |   | potassium chloride (KCl) oral once daily  | KCl BID-QID (for daily doses less than 25 mEq)   |
|                                 |   | hand-held inhalers (with spacer if possible)  | nebulizers   |
|                                 |   | gliclazide MR: give total daily dose once daily   | gliclazide MR daily dose split BID or TID  |
|                                 | tiotropium once daily <sup>8</sup>  | ipratropium QID   |  |
|                                 | Breo Ellipta once daily <sup>8</sup>  | Advair or Symbicort BID   |  |
|                                 | Alvesco or Arnuity Ellipta once daily <sup>8</sup>  | Flovent or Pulmicort BID  |  |

| Strategy  | Description  | Specific Examples (note: not an extensive list) <sup>1</sup>   |  |
|---|--|--|--|
|   | Change from short acting to long acting formulations as clinically appropriate | using single pill combinations (e.g., for antihypertensive drugs)  |  |
|   |  | step down from IV to oral antibiotics as soon as clinically appropriate  |  |
|   |  | <b>Consider:</b>   | <b>Instead of:</b>                               |
|   |  | phenytoin extended release once daily (max 400mg/dose)   | phenytoin same daily dose split BID or TID       |
|   |  | metoprolol SR once daily   | metoprolol BID                                   |
|   |  | long-acting basal insulin (e.g. glargine) daily  | Intermediate acting basal insulin (e.g. NPH) BID |
|   |  | bupropion XL once daily  | bupropion SR                                     |
|   |  | MacroBID BID   | nitrofurantoin QID                               |
|   |  | Opioids: change to long acting formulations when tapering and discontinuing therapy is not possible; this also allows for consolidating with laxative regimens |  |
| <b>Reducing the frequency of medication-associated monitoring</b> | Minimize monitoring in stable patients   | Oral diabetes medications: reduce blood glucose monitoring in inpatient settings   |  |
|   | For new therapy, select medications that minimize monitoring where possible    | Choose antibiotics not known to interact with warfarin in patients not otherwise needing frequent INR monitoring   |  |
|   | Bundle medication monitoring with other labs when possible                     | Draw drug levels on days patients already have other lab work scheduled  |  |

1. For more strategies, please see: <https://www.pharmacy.umaryland.edu/centers/lamy/optimizing-medication-management-during-covid19-pandemic/>
2. Centre for Effective Practice Management of Chronic Non-Cancer Pain <https://cep.health/clinical-products/chronic-non-cancer-pain/>
3. Centre for Effective Practice Opioid Tapering Template <https://cep.health/clinical-products/opioid-tapering-template/>
4. CADTH: <https://www.cadth.ca/dioctyl-sulfosuccinate-or-docusate-calcium-or-sodium-prevention-or-management-constipation-review>
5. Shared Care BC – You Decide Statins in the Older Adult [http://www.sharedcarebc.ca/sites/default/files/SC-PP-Statins%20You%20Decide-V-2017-01-07\\_0.pdf](http://www.sharedcarebc.ca/sites/default/files/SC-PP-Statins%20You%20Decide-V-2017-01-07_0.pdf)
6. A Guide to Deprescribing Statins (Australia) <https://www.primaryhealthtas.com.au/wp-content/uploads/2018/09/A-Guide-to-Deprescribing-Statins.pdf>
7. Statins in the Elderly (College of Physicians and Surgeons Alberta) <http://www.cpsa.ca/statins-in-the-elderly/>
8. For more examples of once daily regimes for stable patients see:  
Asthma: [https://cts-sct.ca/wp-content/uploads/2020/04/FINAL-April-13\\_CTS-re-Asthma-Salbutamol-Shortage.pdf](https://cts-sct.ca/wp-content/uploads/2020/04/FINAL-April-13_CTS-re-Asthma-Salbutamol-Shortage.pdf);  
COPD: <https://cts-sct.ca/wp-content/uploads/2020/04/FINAL-April-13-CTS-re-COPD-Salbutamol-Shortage.pdf>